Research teams from the United Kingdom and Germany have published their results in the Advance Online Publication on the website of Nature Cell Biology.

The teams belong to the Centre for Molecular Biology at the University of Heidelberg and to the Department of Biochemistry at the University of Leicester. The work of the teams had the support of the DFG (German Research Foundation), Wellcome Trust, Cancer Research UK and the Association for International Cancer Research.

The study was led by Professor Elmar Schiebel from the University of Heidelberg who said that the study described new and important insights into a fundamental process involved in the division of the cell. The results suggest new approaches to a targeted treatment of cancer.

The leader of the team belonging to the University of Leicester, Professor Andrew Fry, added that this exciting new development offered potential for identifying new ways of inhibiting unregulated division of the cell which was characteristic to cancer. The team already works with other colleagues in London and Newcastle to develop the research.

Investigators of the processes involved in the division of the cell identified a new potential breakthrough. As Professor Fry explained, when cells divide they have to accurately separate the genetic material of a scaffolding structure, the mitotic spindle. Cells divide in two and therefore the mitotic spindle scaffold presents two poles to which genetic material, which is carried on chromosomes, must separate.

The poles of this spindle are generated by centrosomes, which are normally held in the close proximity in cells. At the start of the division, they move to the cell’s opposite ends. When the centrosome separation fails, the division of the cell is blocked and this process can lead to the death of the cell.

As the researchers said, their studies identified new proteins that are in control of centrosome separation and assessed the relative contribution of these together with regulators described previously. The research suggests new approaches to targeted treatment of all diseases characterised by irregular cell division, such as cancer is. Inhibitors of centrosome separation may have the potential to prevent anarchical proliferation of cells.

Combining drugs against several regulators may also reduce cytotoxic side-effects thanks to the reduced concentration of each inhibitor used in patients.

The teams of researchers are now developing inhibitors against centrosome separation regulators in order to undertake proofs of principle experiments. They collaborate with the Institute of Cancer Research in London and also the Northern institute for Cancer Research at the Newcastle University.

Results obtained in a phase I clinical study of the new drug were presented in Berlin, on November 19th, at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. ACE-041 aims at the receptor known as ALK-1 (activin receptor-like kinase-1), which is responsible for regulating the formation of new networks containing blood vessels that are needed for the growth of tumours. This process is known as angiogenesis. Existing anti-angiogenic drugs, including sunitinib, bevacizumab and sorafenib are targeting other angiogenesis receptors like VEGF, while ACE-041 is among the first drugs to target the ALK-1.

Professor Sunil Sharma, who is the Jon and Karen Huntsman Presidential Professor of Cancer Research at the Huntsman Cancer Institute of the Utah University in Salt Lake City, USA, said that the connection between angiogenesis and ALK-1 was made by discovering that mutations in the ALK-1 gene had caused a condition named HHT2 (hereditary haemorrhagic telangiectasia 2, characterised by diminished formation of capillary beds, which causes red markings at the level of the skin.

A technology company in Cambridge, Massachusetts, USA, Acceleron Pharma, has designed ACE-041 aiming to inhibit ALK-1 signalling and has asked Professor Sharma to be one of the investigators who would conduct the first-in-man phase I clinical test of the drug in order to see if it really would halt tumour angiogenesis.

Professor Sharma said that since ALK-1 was transiently expressed on proliferating cells lining the inner surface of the blood vessels (endothelial cells), while VEGF receptors were constitutively expressed on endothelial cells and other types too, it would be a more selective target when trying to inhibit angiogenesis. ALK-1 expression on the vasculature of the tumour has been noticed on biopsy samples of a wide range of tumours.

The phase I of the study comprised patients with a diversified range of advanced solid tumours that already spread to other parts of the body or simply were inoperable like multiple myeloma, neck and head cancers, NSCLC (non-small cell lung cancer) and carcinoid tumours (carcinoma type neuroendocrine tumours usually originating in the appendix or small intestine). Many of the patients had been unsuccessfully treated with a series of other treatments, which included anti-VEGF drugs, before this trial. ACE-041 has been administrated via subcutaneous injections.

Professor Sharma said that, early in September, 25 patients have been included in the study and ACE-041 dose level has been escalated from 0.1 mg/kg to 4.8 mg/kg. In the case of a patient with neck and head cancer, the response was partial, while three patients have shown positive responses as determined by FDG-PET scans. ACE-041 has been well tolerated by the patients, with some adverse events like peripheral oedema, anaemia, headache, nausea and fatigue.

Seeing many signs of efficacy during the trial has been quite encouraging for the medical team, particularly because of the structure of the study population. They were patients with end-stage cancer, already treated with and refractory to multiple standard therapies. It has equally been encouraging to note signals of activity of ACE-041 in a wide series of tumour types, thus confirming the hypothesis that ACE-041 may really act against tumours with agiogenic activity, no matter what histology they had. Another important aspect to be noted was the demonstration of the significant activity with ACE-041 monotherapy during the study, which leads to expectations of more efficacy in future studies including ACE-041 combined with other therapies.

Professor Sharma and his team planned further investigations related to the safety and tolerability of ACE-041 in an additional group of cancer patients and look forward to start a phase II study in 2011.

According to Professor Sharma, the anti-VEGF angiogene inhibitors, which include sunitinib, bevacizumab and sorafenib, have represented an important contribution to the armamentarium of therapies against cancer. However, the efficacy is in a way limited because tumours could eventually develop an ability to simulate angiogenesis using non-VEGF angiogenic factors. Serious side-effects appear from effects on blood vessels found in normal tissues. ACE-041 inhibits angiogenesis in a totally different way and therefore it might have synergistic efficacy with VEGF-based inhibitors. It may be effective for patients who have manifested resistance to VEGF inhibitors.

In the United States, lung cancer is the second most found type of cancer. It accounts for more dead people than prostate, breast and colon cancer together, as data from the Centers for Disease Control and Prevention show. Many patients follow more than a single type of treatment for lung cancer, which can last for some weeks to months.

Raimar Löbenberg, lead researcher, and his team mates Wilson Roa and Warren Finlay from the University of Alberta, using a usual chemotherapy drug which was encapsulated into nanoparticles, developed a dry powder to be inhaled.
A number of mice were treated with this powder and others received the same drug through two distinct delivery methods, consisting of a solution and intravenous injection of drug bound nanoparticles.

Results have shown the inhalable dry powder as being more effective than the solution or the intravenous injection. According to the study, more than eighty percent of the mice lived more than ninety days. More than seventy percent of the mice lived for 140 days. At the same time, none of the animals treated with the solution or the intravenous injection survived more than fifty days.

Löbenberg said that current treatments for lung cancer could cost the patient a lot. The research showed that the new treatment method might increase the survival rate and at the same time could be less toxic for the patients’ bodies.

The new inhalable dry powder also proved its efficiency versus the intravenous injection in reducing both the amount and the size of tumors. The animals not treated or treated with the solution or intravenous injection presented large tumor masses, while mice treated with the inhalable dry powder showed significantly fewer and also smaller tumors.

Mitch McVey, Assistant Professor of Biology, and his team of researchers report that PolQ (DNA polymerase theta) could promote a wrong repair process, supposed to be the cause of mutations, cell death and even cancer. The research has been published in the open-access PLoS Genetics journal, the 1st of July edition.

Scientists have been aware for many years that the DNA polymerase theta is in a way related to cancer development, but the exact cellular role it has is difficult to reveal, according to McVey. It is known that its action during incorrect DNA repair might have implications for those biologists who analyze genomic modifications associated with cancer.

The DNA molecule is double stranded and shaped in the form of a spiral staircase. The two strands are connected together by nucleotides like adenine, cytosine, guanine and thymine, which naturally complement each other. Under normal circumstances, a guanine nucleotide corresponds to a cytosine, while an adenine corresponds to a thymine.

During a cell’s life, it may occur that the staircase is cut off into two molecules. The breaks are to be repaired if cells are supposed to replicate accurately and transmit their genetic material. An important part of these breaks is fixed fast and accurately during a process named HR (homologous recombination). This process uses for repair a template formed of an intact DNA copy. There is, however, a second process, named end-joining repair, which is susceptible of errors. It stitches back together the broken stranded ends without considering the original sequence. Thus, the ends of the strands may be modified by addition or removal of little DNA segments that could alter the genomic architecture.

Mitch McVey and Amy Marie Yu, a doctoral student, have demonstrated an alternative structure of end-joining after studying how repair goes on when DNA ligase 4 is absent. DNA ligase 4 is an important protein which connects together two broken ends of DNA.

Two things have been observed during the analysis of breaks inaccurately repaired in Drosophila melanogaster, the fruit fly. One thing was that extra nucleotides were added to the DNA strands were the breaks were present. Secondly, the insertions were tightly related to the DNA original sequences that were adjacent to the breaks.

The authors have shown that polymerase theta has a dominant role to play in the alternative repair process. It reads first the genetic material present in the DNA neighboring the break and constructs a copy of its structure. The copy of the DNA is then used as a molecular sliver which holds together the ends of the broken strand until they are able to join permanently. The PolQ protein is also believed to be able to unwind the sequences of DNA in the neighborghood of a break and this way facilitates alternative end-joining.

Levels of the protein have been demonstrated to be higher in many types of tumors present at the human, as other groups of researchers have previously shown. McVey’s team is currently working to find out if an alternative type of end-joining depending on the PolQ protein is eventually involved in human cancer. If this is found to be true, then there would be a new target for developing new cancer drugs and this would be the PolQ protein. The first goal of the team is to establish which parts of the protein are playing an active role in alternative end-joining. This could give the team a road map for studying how the activity of the protein has to be altered in order to achieve the expected results.

The National Science Foundation together with the Ellison Medical Foundation has funded the work of McVey’s team.

The investigation was released in the Cancer Research journal in its October edition. The investigators from the University of Texas Southwestern Medical Center discovered that if they gave the mice the BEZ235 medication prior to undergoing harmless radiation in order to counteract the cancerous cell development of DNA, the BEZ235 would counteract the activity of the PI3K protein which typically acts as a guardian of the tumor cells. This protein maintains the cancerous cells in life in the moment they are attacked and try to heal their broken DNA.

Besides the leading author, the team of investigators from the University of Texas comprised: doctor Erik Bey from the Harold C. Simmons Comprehensive Cancer Center, doctor Andrea Rabellino, doctor Katja Schuster, doctor Adi Gazdar, professor within the University of Texas Southwestern, Jake Hamon from the Center for Therapeutic Oncology Research, doctor David Boothman from the Simmons Comprehensive Cancer, researchers coming from the University of Camerino in Italy and Novartis Pharma in Switzerland. Their investigation was financed by funds coming from National Institutes of Health, American Cancer Society, Concern Foundation, Gibson Foundation, Leukemia of Texas, United States Department of Energy and the American Italian Cancer Foundation.

The scientists observed this treatment opportunity in mice that underwent a transplant process with non-small cell lung cancer tumors from human beings.

During their observation process, the researchers discovered that the malignant tumors developing in the mice which were treated with just the BEZ235 has a decrease in size compared to those affecting mice which were not undergoing any type of treatments. Even though the malignant tumors did not grow in size, their life was not ended by administering the specific medication.

On the other hand, mice undergoing the BEZ235 treatment combined with low-dose radiation recorded many cases of total elimination of the malignant tumors.

The leading investigator was doctor Pier Paolo Scaglioni who is assistant professor of the internal medicine department within the University of Texas Southwestern. He stated that the findings of his research team regarding the combination of medication and low-dose radiation may prove to become an efficient treatment for counteracting non-small cell lung cancer in human beings.

The non-small cell lung cancer represents one of the main causes of cancer connected mortality on the whole Globe. The malignant cells usually favor transformations in the K-RAS which is a gene. People suffering from mutations of the K-RAS usually present an increased resistance to therapies comprising irradiation. This is the cause for which their life perspectives are unfavorable.

The K-RAS transformations trigger the networks or different pathways of various proteins that act as signals to activate. This signaling represents a key element in the development and growth of a malignant tumor. The PI3K represents just one of these proteins. At the moment of activation, it acts as a guardian which aids the cells in maintaining living functions even after their DNA was damaged and they try to heal it.

Some of the elements forming the signal networks comprising also the PI3K protein have been explored as various medication targets for counteracting malignant tumors. The clinical tested medication BEZ235 has been recently in experiments comprising clinical tests for counteracting the activity of the PI3K and the mTOR which represents a signaling protein, also.

As the leading investigator states there is no efficient treatment counteracting the non-small cell lung cancer which hosts transformations of the K-RAS.

Medical doctor Pier Paolo Scaglioni conducted the first tests in order to identify the efficacy of the BEZ235 drug and thus, they tested it alone. The team of investigators discovered that the BEZ235 stops the evolution and growth of the lung cancer malignant cells that were developed in the laboratory and the malignant lung cells that affect the mice.

As the leading author of this first research, doctor Georgia Konstantinidou states the findings of the investigators were shocking. However, they strived to discover a way for a faster malignant cell deterioration. They found put that by combining the tested medication with low-dose radiation, the success of their mission was assured. Doctor Georgia Konstantinidou is a post-doctoral scientist within the University of Texas Southwestern.

Doctor Pier Paolo Scaglioni`s research group observed that the malignant cells which were treated with the BEZ235 medication and low-dosed irradiation. The latter triggered slight breaks in the cellular genetic material but did not managed to affect them in a more effective way in order to destroy them. At the moment the DNA of the cell is broken, the malignant cells are aided by the PI3K signaling network in order to assure the cancer cell`s survival while it is healing its genetic material.

The team of investigators explained that the malignant cells needed the PI3K signaling pathway to assure they remain alive and without the protein`s response they were prone to die. This is why in the moment the scientists administered the BEZ235 medication it stopped the action of the PI3K protein and this means that the non-small cell lung cancer cells were starting to die.

As the leading author of the research explains the future stage of the study is that of administering the BEZ235 medication or similar drugs in clinical tests against the non-small cell lung suffering human beings. This could also be applied in clinical trials comprising people suffering from other types of malignant cells such as pancreatic, colon and thyroid cancers. There are the same with the non-small cell lung due to the fact that the PI3K signaling network also acts as an important agent in the malignant cells` evolution.

This environmental report is just a part of the process of taking care of the continuous and newly discovered problems regarding the pollutant agents of the environment and cancer. Moreover, the scope of the report is to shed more light on the principles, mission, values, objectives and various roles of the American Cancer Society on issues such as those mentioned before: pollution and malignant tumors prevention.

As the co-chair of the subcommittee and chairman of the Department of Preventive Medicine within the Keck School of Medicine of University of Southern California, medical doctor Jonathan Samet explains the problems regarding the environmental pollution agents affecting the air, water, food and thus, customer products represent issues on general public care and high unknowns. He also adds that their report aims to put the pollution agents of the environment in a greater relationship with preventing malignant tumors. The relationship focuses on reducing the smoking habit of the population, improving nutritional behavior, increasing the physical activities, maintaining a proper body weight and come up with vaccines that counteract the infections which may cause cancers.

The other co-chair of the subcommittee is also volunteer president of the American Cancer Society. Her name is Elizabeth “Terry” T.H. Fontham and she stated that the exposure levels of the population to chemical and pollution agents affecting the environment are much lower than the levels linked to the showed predisposition to developing malignant tumors in the jobs people have and other daily settings. However, the concern raised by the low exposure levels has to do with the fact that the number and types of pollution substances are increasing and may prove in the future to get out of the population`s control. In addition, the problems related to the fact that even low exposure levels bring some contribution to the cancer developing cases cause more reasons for distress considering the high number of persons who are daily exposed to the environmental pollutants.

The subcommittee`s report states that the scientific problems related to the exposure of people to the environmental pollutants represent complex issues just like increase in the number of landscape technologies which are utilized to analyze the chemical carcinogenicity. In spite of the capability of the nowadays tools used to identify and categorize proves for carcinogenicity, the subcommittee`s article states that there exist three main problems which constrain them from using them because there is a limited quantity of resources which are allotted to function those specific systems and from a scientific point of view, the environmental problems are complex and uncertain.

The report`s concerns about cancer vary and are related to malignant tumors prevention. There is a high need for new stratagems related to the tests done to evaluate the environment`s toxicity, comprising also the evaluation of carcinogenicity. These new strategies could be incorporated in such a manner as to assure a more efficient and effective screening process of a higher number of chemical agents which affect people daily. In addition, exposure to occupational and community settings should be regulated by some standards. The subcommittee draws attention on the need to support investigations aimed at identifying and decreasing the number of hazards provoked by carcinogens. Furthermore, the institutions that determine and implement standards for the environment must meet proper financing and appropriate technology in order to be near the scientific evolution and upgrade their set standards according to the new available data.

Even though some exposure cannot be avoided, this type of exposure must be somehow diminished and even stopped in the cases where it is possible to do so. In addition, the population must receive information about these matters in order to know their health status and risk of cancer or other diseases. Last, but not least, the media communication must make people aware of the situation of the exposure in an accurate manner and not to exaggerate or diminish the importance and level of environmental pollution factors.

The subcommittee’s report states that in order to create and implement this new initiative in order to assure the acquiring of more knowledge regarding the association between the levels of exposure to environmental pollution agents and the predisposition to various types of cancers, the American Cancer Society is going to further develop its long-run commitment to preventing malignant tumors. In addition, the American Cancer Society is also keen on studying these problems more thorough in order to discover new ways in which the initiative could bring more benefits in an effective and efficient manner.

The MASCOT project was financed in part by the European Commission (IST-027652).

This device is the first of its kind because it comprises various significant preparation phases for samples and muxing based detection which was created and implemented in the lab-on chip. An interesting fact is that all the module complexes for investigating and mingling with the samples and the detection feature of the gadget are preparing to be even further minimized in order to be incorporated in just one lab-on-chip device. The researchers desire that this complex would become feasible in a medical manner in the Oslo during the studies of breast cancer treatments.

A great thing is that this circulating cancer diagnosis represents an important methodology for a personalized tracking of people who suffer from malignant tumors both in an early development stage and in an advanced one. This, in turn, would lead to an improvement in the physicians and surgeons` decision-making ability.

Taking into consideration breast cancer, 5 milliliters of blood comprise just two or three cells coming from tumors. In order to find out from the blood tests if someone has developed malignant tumors, the malignant cells circulating in the blood flow have to be isolated, caught and their genetics have to be observed.

The nowadays diagnostics done in the labs of the medical facilities are not time- and cost-effective and require a lot of work. This type of diagnosis might ask for a number of processing phases for the sample in various medical tools so the complete analysis of the sample is for sure to take more than 24 hours. On the other hand, the lab-on-chip technology could have many benefits for the entire medical world and the people who are ill. This innovative system is cost-effective, has easy usage and is very fast compared to the past methods. An interesting aspect of this technology is that it does not need medical laboratories and laborious hours. Instead, the tests comprised by the lab-on-chip can be undergone routinely either in the physician`s office or nearby the bed of the sick person. Thus, the lab-on-chip technology represent a time saving opportunity which does not require laborious work do be done in order to get the results to diagnosis tests. Moreover, it provides the minimum of body invasion in order to discover cancer cells and a customized treatment and screening.

The study`s collaborators created a modular platform in which every module performed a specific job and kept its independence. This endowment means that the technology can be utilized in numerous medical tests. The first module of the platform is the incubation one which has the role of mixing the blood under testing with specialized magnetic beads in order to link the tumor cells to one another. The second module has the role to isolate the malignant cells and count them thanks to a magnetic characteristic which can attract each cell and dielectrophoresis function. The third one is entitled the amplification module. It has the role to destroy the wall comprising malignant cells and by doing this the mRNA, the desired genetic material, is taken out from the sample and enhanced by using MLPA (multiplex ligation dependent probe amplification).

In the third module, certain procedures that measure the biochemical substances from the extracted substance enhance approximately twenty markers that are generated in the carcinoma cells of the breast. In the last module used for detection, the enhanced genetic substance is discovered by utilizing a series of electrochemical markers. These modules have been created and are feasible to use on the samples of blood.

The modules are prepared for advanced incorporation in just one lab-on-chip. By minimizing the size and linking the micofluidic and electronic functions of the technology, their accuracy and trustworthy character is enhanced in order to perform tests on sick people. The medical utilization of the lab-on-chip is going to be observed in order to see its similarities and differences compared to the existing methodologies used in the breast cancer treatments. This is going to be accomplished by a new investigation.

In order to complete the research, the multi-organizational group of investigators observed the telomeres of Arabidopsis which is a weed located everywhere around the Globe and found out that it contains a set of proteins that people did not know anything about. After this discovery, the investigators found its human correspondent. This result might prove to be advantageous for comprehending better the nature of cancer and cell`s life span. The investigation`s findings were released in the Molecular Cell journal. The research was financed by the National Institutes of Health.

Professor of biophysics and biochemistry within Texas A&M University, Mrs. Dorothy Shippen and Carolyn Price, her counterpart from the University of Cincinnati College of Medicine, professor of cell biology and cancer, were the co-authors of this investigation.

The telomeres are found in the chromosomes in their every end and comprise DNA and protein. Their primary role is to defend their location and are also essential factors regarding the cellular division process. Scientists also think that telomeres are essential elements in the lifetime duration of the cells.

As Dorothy Shippen states the team of researchers discovered that by removing the telomere proteins from the common weed, its chromosomes would join their ends in an aggressive manner, a process which would trigger significant problems in the Arabidopsis` evolution.

The investigation team proved that by removing just one human protein from the human malignant cells would cause a great DNA defect and the whole loss of some of the telomeres. In addition, the researchers state that they knew that the telomeres were a protective hat for the chromosomes which were a must in inhibiting the chromosomal fusions. Moreover, their length determines the cell`s division number. Nonetheless, the scientists still do not completely comprehend the way the hat structure prevents the chromosomal fusions or how it sets the length of the telomeres. These are considered very important issues due to the fact that if the telomeres are not maintained properly, illnesses like pulmonary fibrosis, premature aging syndromes, aplastic anemia and cancer could develop. The team of investigators aims to find a new protein complex which is needed in order to keep the benefic telomere hat on the chromosomes and they hope that this would lead the way for innovative studied associated with the illnesses affecting human beings.

The common weed, Arabidopsis, is present all over the Globe and is part of the cabbage, radish and mustard plant family of plants. Due to its genetic architecture, the Arabidopsis has been long studied as a standard “lab plant” in researches related to the cells and molecules coming from plants with flowers.

The multi-organizational investigation group states that their discoveries pave the way for new researches, which could end up with an innovative finding regarding the telomeres.

As one of the leading authors explains, future study in this matter would bring more knowledge regarding the telomeres` composition and their functionality. This, in turn, would provide scientists with a chance in finding the precise roles of the telomeres as guardians of the human beings` DNA. In addition, the future research could present the big picture of the manner in which damages to the telomeres inhibit the division process of the cells. Having discovered that the proteins act as essential actors in the DNA replication in the end of the chromosomes, the investigators suggest that new investigations should be undergone in order to gain more knowledge about just how the guardian hats function during the cellular division. As a conclusion, one of the leading investigators states that all these issues have to lead to answers in order to gather a complete understanding of the telomeres` roles in human beings.

The COX-2 (Cyclooxgenase-2) represents an enzyme which synthesizes prostaglandin. An evolved expression of Cyclooxgenase-2 is found in a great variety of malignant tumors affecting human beings which also comprise the gastric cancer. Experiments done on animals revealed that a long-term treatment with medication that inhibits the gastric carcinogenesis related to Cyclooxgenase-2. However, using such inhibiting drugs on humans is still not done due to the fact that the medication can trigger harmful and even fatal cardiovascular side-effects. This is why it is of great importance to discover the best and harmless therapy comprising Cyclooxgenase-2 inhibiting medications that also inhibit the Helicobacter pylori linked to gastric carcinogenesis.

A recent study regarding this matter was released in the World Journal of Gastroenterology in the October edition. Professor Wu coming from the Department of Gastroenterology within the Kaohsiung Medical University Hospital was the leader of the investigation. He utilized the Mongolian gerbil model in order to observe the best point of Cyclooxgenase-2 inhibiting medication for inhibiting gastric carcinogenesis produced by Helicobacter pylori. This new research also takes a closer look at the chemotherapy use for preventing this condition and also at the adverse effects the Cyclooxgenase-2 inhibiting medication may produce to the human body.

Earlier investigations utilized chemotherapies on a long-run basis for preventing the gastric carcinogenesis. Nonetheless, the Cyclooxgenase-2 inhibiting drugs did not come in placebo format and affected the patients. This group of medications must not be utilized on a long-run basis in the chemoprevention of the gastric malignant tumors.

As the investigation pointed, Celecoxib is a drug which might trigger anti-oncogenic effects. It can also inhibit the angiogenesis and the spreading of malignant tumors in the whole body. Moreover, this medication proved to be efficient in obtaining these effects either if it was used on a short- or a long- term basis. Celecoxib acted as a guardian who connotes an early oncogenic stage and not an inflammatory one. In addition, the utilization on short-term of Celecoxib proved to bring harmless inflammations and also stopped the spreading of gastric malignant cells in the organism.

If we were to listen to what the investigation has to say, the short- and long-term use of Celecoxib for counteracting Helicobacter pylori` infection pathway in a medical case is the best thing to do. This finding has been never present in earlier researches. Thus, the new discovery is essential in diminishing the adverse effects produced by Cyclooxgenase-2 inhibiting drugs.

The team of investigators state that Cyclooxgenase-2 inhibiting medication might be utilized as a chemoprevention treatment for patients that are 40 years or older. This approach may prove to play an essential part in the life of patients who suffer from extended metaplastic gastritis with an enhanced predisposition of developing gastric malignant tumors. Moreover, the therapy is essential also for people who suffer from refractory Helicobacter pylori infections with an increased predisposition for gastric malignant tumors.

As a gastroenterological specialist stated the research outcome provides new insights into a customized treatment against gastric malignant tumors starting with the prevention phase and also it may bring advantages for medical therapy in the near future.
.